MYGN Q4 2021 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q4 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$161M

Gross Profit

$115M71.5% margin

Operating Income

-$43M-26.8% margin

Net Income

-$8M-4.7% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-3.9%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$13M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$353M

Stockholders' Equity

$968M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$161M	$0	—
Gross Profit	$115M	$0	—
Operating Income	-$43M	$0	—
Net Income	-$8M	$0	—

Geographic Segments

UNITED STATES

$17M62%

Non-US

$10M38%